Generative AI designs new DNA sequences to turn genes on and off
AI can dramatically accelerate the time to design new DNA sequences for healthcare purposes - but it can also be weaponised.
Key takeaways
- The breakthrough could pave the way for improved gene therapies.
- Researchers describe the new AI platform, called Computational Optimization of DNA Activity (CODA), in an article published October 23rd in Nature.
- The CODA tool creates DNA sequences, called cis-regulatory elements (CREs), which use a complex code to activate genes in specific cells.
Cite or link to this article
Griffin, M. (2024) 'Generative AI designs new DNA sequences to turn genes on and off', 311 Institute, 24 February. Available at: https://www.311institute.com/generative-ai-designs-new-dna-sequences-to-turn-genes-on-and-off/ (Accessed: 1 October 2026).
Over the past year or so Artificial Intelligence (AI) has discovered new CRISPRs, created new artificial human genomes, and more basic genomes, and now ateam of researchers from Yale School of Medicine (YSM), the Jackson Laboratory, and the Broad Institute of MIT and Harvard has developed a new AI tool capable of designing never-before-seen sequences of synthetic DNA capable of switching on targeted genes in specific cells. The breakthrough could pave the way for improved gene therapies.
Researchers describe the new AI platform, called Computational Optimization of DNA Activity (CODA), in an article published October 23rd in Nature.
The authors say while gene therapies hold the potential to rewrite disease-causing mutations, better methods are needed to deliver the therapy directly to cells that harbor disease, while leaving it inactive in other parts of the body where it could cause harm. The CODA tool creates DNA sequences, called cis-regulatory elements (CREs), which use a complex code to activate genes in specific cells.
“This project essentially asks the question: ‘Can we learn to read and write the code of these regulatory elements?’” said Steven Reilly, PhD, assistant professor of genetics at YSM and one of the senior authors of the study. “If we think about it in terms of language, the grammar and syntax of these elements is poorly understood. And so, we tried to build machine learning methods that could learn a more complex code than we could do on our own.”
The team trained its model on over 775,000 naturally-occurring CREs tested in blood, liver, and brain-related cell types, then tested the novel, AI-generated CREs in the same type of cells. Researchers say in many cases, the synthetic CREs were more specific to a given cell type than natural ones.
“There are a lot of potential solutions out there for lots of different possible things you might want a regulatory element to do,” Reilly said. “Evolution maybe has never wanted to build a really great driver for an Alzheimer’s drug, but that doesn’t mean it can’t exist.”
The paper's first authors were Rodrigo Castro, PhD, of the Jackson Laboratory and Sager Gosai, PhD, of the Broad Institute. The senior authors were Steven Reilly, PhD, of Yale School of Medicine, Pardis Sabeti, PhD, of the Broad Institute, and Ryan Tewhey, PhD, of the Jackson Laboratory.
FAQ
Why does this matter?
AI can dramatically accelerate the time to design new DNA sequences for healthcare purposes - but it can also be weaponised.
About the author
Matthew Griffin Founder, 311 Institute
Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath."
Read full bio
Matthew Griffin is a multi-award winning Futurist and expert in Disruption and Innovation, Geopolitics, Leadership, and Technology, who NASA have described as a "walking encyclopaedia of the future" and a "futurist Polymath." 15-time best selling author of the "Codex of the Future" series, Matthew is the Founder and Futurist in Chief of the 311 Institute, a global Futures and Deep Futures advisory firm working with royal households, world leaders, G7, G20, and G77 governments, NGOs, and multi-national mid and mega cap firms to help them explore, shape, and lead the next 50 years of business and society.
An award-winning YouTube creator with over a million followers, with an unrivalled global reach and impact, Matthew is a highly sought-after international keynote speaker, lecturer, and mentor who collaborates with global leaders through the United Nations Alliance of Civilizations (UNAOC) and United Nations General Assembly (UNGA) to shape pivotal initiatives such as the UN’s AI for Humanity program, the United Nations Conference of the Parties (UN COP), and the World Economic Forum in Davos.
As the former Global Head of Cloud, National Security, and Enterprise Sales for companies including Atos, Dell-EMC, and IBM, Matthew has a proven track record of building multi-billion dollar business units and turning failing divisions into market leaders. His ability to identify, analyse, and communicate the implications of hundreds of emerging technologies and trends is unparalleled, and his insights are trusted by many of the world’s most respected organisations, including ABB, Accenture, Adidas, AON, ARM, BCG, Centrica, Citi, Coca-Cola, Dentons, Deloitte, Dow Jones, EY, Google, KPMG, Lego, Legal & General, LinkedIn, Microsoft, PepsiCo, Qualcomm, RWE, Samsung, Siemens AG and Siemens Energy, T-Mobile, UBS, VISA, Walmart, Workday, Worldpay and many others.
Regularly featured in the global media including the AP, BBC, Bloomberg, CNBC, Discovery, Forbes, Khaleej Times, Telegraph, TIME, ViacomCBS, WIRED, and the WSJ, Matthews mission is to help organisations create a fair and sustainable future whose benefits are shared by everyone irrespective of their ability, background, or circumstances.
What future do you need to see?
Choose one to get started on biotech and enhanced humans and the future of your organisation.
Sources and further reading
- Steven Reilly, PhD medicine.yale.edu
Source: first published by the 311 Institute on 24 February 2024. Cite as: Griffin, M. (2024). Generative AI designs new DNA sequences to turn genes on and off. 311 Institute. https://www.311institute.com/generative-ai-designs-new-dna-sequences-to-turn-genes-on-and-off/
You are welcome to quote this article with credit and a link to the original.